Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Journal of Clinical Pharmacology
|
March 24, 2006
Race and ethnicity in the era of emerging pharmacogenomics
Lea Harty, Keith Johnson, Aidan Power
Current Topics in Medicinal Chemistry
|
September 27, 2005
Pharmacogenomics: integration into drug discovery and development
Keith Johnson, John Thompson, Aidan Power
International Journal of Molecular Sciences
|
July 2, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar, John Hey, Aidan Power, et al.
Plos One
|
October 27, 2022
Medical student wellness assessment beyond anxiety and depression: A scoping review
Kay-Anne Haykal, Lara Pereira, Aidan Power, et al.
International Journal of Molecular Sciences
|
March 13, 2024
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
Martin Tolar, John A Hey, Aidan Power, et al.
The Journal of Clinical Psychiatry
|
June 29, 2002
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia
Steven R Hirsch, Werner Kissling, Josef Bäuml, et al.
Pharmacogenomics
|
December 24, 2008
Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1
Martin Armstrong, Christina Bromley, Nadine Cohen, et al.
Pharmacogenomics
|
December 15, 2010
Designing pharmacogenomic studies to be fit for purpose
Daniel K Burns, Arlene R Hughes, Aidan Power, et al.
Drugs
|
June 20, 2024
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model
John A Hey, Jeremy Y Yu, Susan Abushakra, et al.
CNS Drugs
|
November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
John A Hey, Petr Kocis, Jakub Hort, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Journal of Clinical Pharmacology
|
March 24, 2006
Race and ethnicity in the era of emerging pharmacogenomics
Lea Harty, Keith Johnson, Aidan Power
Current Topics in Medicinal Chemistry
|
September 27, 2005
Pharmacogenomics: integration into drug discovery and development
Keith Johnson, John Thompson, Aidan Power
International Journal of Molecular Sciences
|
July 2, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar, John Hey, Aidan Power, et al.
Plos One
|
October 27, 2022
Medical student wellness assessment beyond anxiety and depression: A scoping review
Kay-Anne Haykal, Lara Pereira, Aidan Power, et al.
International Journal of Molecular Sciences
|
March 13, 2024
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
Martin Tolar, John A Hey, Aidan Power, et al.
The Journal of Clinical Psychiatry
|
June 29, 2002
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia
Steven R Hirsch, Werner Kissling, Josef Bäuml, et al.
Pharmacogenomics
|
December 24, 2008
Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1
Martin Armstrong, Christina Bromley, Nadine Cohen, et al.
Pharmacogenomics
|
December 15, 2010
Designing pharmacogenomic studies to be fit for purpose
Daniel K Burns, Arlene R Hughes, Aidan Power, et al.
Drugs
|
June 20, 2024
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model
John A Hey, Jeremy Y Yu, Susan Abushakra, et al.
CNS Drugs
|
November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
John A Hey, Petr Kocis, Jakub Hort, et al.
Page
of 2